MN-ENTRUST
14.9.2020 15:29:04 CEST | Business Wire | Press release
Entrust Datacard today announced a new brand identity and company name – Entrust . The move both continues the company’s enduring leadership and innovation in identity, payments, and data protection, and highlights Entrust’s position as a leader in developing the core technologies needed to keep the world moving safely.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200914005558/en/
“The global impact of the COVID-19 pandemic has shown us how critical digital transformation is in our daily lives,” said Todd Wilkinson, CEO of Entrust. “As consumers, we depend on digital technologies and security to do more than ever, whether it’s making purchases, crossing borders, accessing government services or logging into corporate networks. We are proud that some of the world’s largest governments, organizations and enterprises trust us to keep citizens, commerce and information moving safely. Making Entrust the foundation of our brand reflects how our technology and innovation are central to securing this ever-evolving world.”
The company was founded as Datacard Corporation in 1969, and acquired Entrust in 2013, becoming Entrust Datacard. Entrust today offers an unmatched breadth of solutions, including credential issuance, identity and data protection, and digital certificates and signing solutions.
Commitment to innovation and growth
In recent years, Entrust has expanded from its core physical credential issuance focus to build a robust digital security solution portfolio and market presence. In addition to a sustained long-term investment in R&D, the company has made a recent series of strategic acquisitions, including PKI providers Trustis and Safelayer, authentication provider SMS Passcode, and nCipher, the market leader in hardware security modules (HSMs).
As a result, Entrust has transformed into one of the world’s largest providers of digital security software, and the global leader in credential issuance solutions. The company is in a unique position to innovate and invest to meet the rising security and identity needs of its customers. Entrust is making significant R&D investments to bring to market new card issuance technology, secure cloud enablement and advancements to its authentication, digital signing, identity management and HSM solutions. The company recently launched its next-generation PKI platform , tailored to meet today’s rising “encrypt everything” demands amidst rising threats, and earlier this year introduced new solutions for passwordless authentication and digital onboarding .
With nearly $800M in annual revenue and 2,500 employees, Entrust is trusted by some of the world’s most demanding, compliance-driven institutions in finance, technology and government. The company provides sales and service in more than 150 countries through 50 offices and a global network of more than 1,000 technology and channel partners.
“Earning the benefits of digital transformation requires a foundation of trust. As identity, payment and data protection ecosystems become more complex and interconnected, trust enables the resiliency and scale needed to make our digital lives possible,” said Frank Dickson, Program VP, Cybersecurity Products, IDC. “Entrust began delivering trust in payment card solutions 50 years ago and has added breadth and depth to its trusted identity and data security solutions ever since. Thus, centering the brand on Entrust makes sense – it helps the market see the common thread of high-assurance trust-building technology that carries through all of its identity, payment and data protection solutions.”
A simplified, refreshed brand
Entrust’s new name and branding honors the company’s heritage as it looks ahead. Datacard will continue to be featured prominently as the product line name for the company’s high-volume card issuance solutions, and the company continues to invest and innovate in high-volume hardware, software, services and supplies. Similarly, while the nCipher name will transition to Entrust over time, the nShield product line name for its market-leading HSMs will be retained and become an Entrust product line.
The branding evolution includes a new logo, brand colors, website, tagline, and positioning that are tightly linked to Entrust’s focus on securing a rapidly changing world.
“In evolving our brand, we wanted to make our mission clear. We come to work every day with one thing in mind: delivering solutions that enable the highest level of trust in every interaction our customers facilitate. Enabling trust is our mission, our value proposition, and the focus of all the innovative technologies we continue to develop for clients worldwide,” said Karen Kaukol, Chief Marketing Officer, Entrust.
To explore the new brand and learn more about Entrust’s products and services, visit www.entrust.com .
About Entrust
Entrust keeps the world moving safely by enabling trusted identities, payments and data protection. Today more than ever, people demand seamless, secure experiences, whether they’re crossing borders, making a purchase, accessing e-government services or logging into corporate networks. Entrust offers an unmatched breadth of digital security and credential issuance solutions at the very heart of all these interactions. With more than 2,500 colleagues, a network of global partners, and customers in over 150 countries, it’s no wonder the world’s most entrusted organizations trust us.
View source version on businesswire.com: https://www.businesswire.com/news/home/20200914005558/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Incyte Announces Positive CHMP Opinion for Opzelura® (ruxolitinib) Cream for the Treatment of Adults with Moderate Atopic Dermatitis26.6.2026 13:30:00 CEST | Press release
If approved, Opzelura® (ruxolitinib) cream will be the first steroid-free, topical JAK treatment option in the European Union (EU) for adults with moderate atopic dermatitis (AD) for whom standard topical therapies have failedAD, the most common type of eczema which affects 230 million people globally,1 is a chronic, recurring, inflammatory and highly pruritic (itchy) skin condition that can have a significant impact on daily life2Phase 3 TRuE‑AD4 data supporting the positive CHMP opinion demonstrated that ruxolitinib cream met both co‑primary endpoints at Week 8, maintained disease control with as-needed treatment through Week 24 and was well tolerated3,4,5 Incyte (Nasdaq: INCY) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has issued a positive opinion recommending the approval of Opzelura® (ruxolitinib) cream for the treatment of moderate atopic dermatitis (AD) in adult patients for whom topical corticosteroids
Datroway® Recommended for Approval in the EU by CHMP as First-Line Treatment for Patients with Metastatic Triple Negative Breast Cancer Who Are Not Candidates for Immunotherapy26.6.2026 13:00:00 CEST | Press release
Recommendation based on TROPION-Breast02 phase 3 trial where Daiichi Sankyo and AstraZeneca’s Datroway showed a statistically significant and clinically meaningful improvement for the dual primary endpoints of overall survival and progression-free survival If approved, Datroway has potential to be the first TROP2 directed antibody drug conjugate for patients in EU with a demonstrated overall survival benefit as first-line treatment Datroway® (datopotamab deruxtecan) has been recommended for approval in the European Union (EU) as monotherapy for the first-line treatment of adult patients with unresectable or metastatic triple negative breast cancer (TNBC) who are not candidates for PD-1/PD-L1 inhibitor therapy. Datroway is a specifically engineered TROP2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use
DAYBU®(trofinetide) Recommended for Approval in the European Union by CHMP26.6.2026 12:49:00 CEST | Press release
-- European Commission decision expected in the coming months-- If approved, DAYBU®would become the first treatment for neurobehavioral symptoms of Rett syndrome in the European Union Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion following a re-examination procedure, recommending the granting of a marketing authorization for DAYBU® (trofinetide) for the treatment of neurobehavioral symptoms of Rett syndrome in adults and pediatric patients aged five years and older. If granted marketing authorization by the European Commission, DAYBU® would be the first therapy approved for this indication in the European Union (EU). “The CHMP’s positive opinion for DAYBU® is an important milestone in our mission to bring this innovative therapy to the EU, where there are no therapies specifically approved for the neurobehavioral symptoms of this devastating
HTEC Showcases Lakebase Branching at Databricks’ Data & AI Summit26.6.2026 11:18:00 CEST | Press release
HTEC, the global technology and AI engineering firm headquartered in Silicon Valley, last week showcased how it used Lakebase data branching to enable faster development, safer operations, and new possibilities for data-driven organizations operating in highly regulated environments. The Solution was developed in collaboration with a leading risk and compliance technology provider who serves financial institutions. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260626875859/en/ HTEC, the global technology and AI engineering firm headquartered in Silicon Valley, last week showcased how it used Lakebase data branching to enable faster development, safer operations, and new possibilities for data-driven organizations operating in highly regulated environments. Solving Critical Development Bottlenecks in Regulated Environments At the core of the collaboration was a shared challenge: how to enable modern data workflows in an envi
Stallergenes Greer Named One of Switzerland’s Best Managed Companies for 202626.6.2026 10:28:00 CEST | Press release
Stallergenes Greer, a global leader in allergy care, has been recognised for its overall business performance, company culture, and sustained growth by receiving the prestigious 2026 Switzerland’s Best Managed Companies award. The 2026 Best Managed Companies programme award winners are among Switzerland’s best private companies. The awards are derived from Deloitte’s global Best Managed Companies awards programme, an internationally recognised programme that evaluates businesses based on their leadership in the areas of strategy, culture and commitment, capabilities, innovation, governance and financial performance. Applicants are evaluated by an independent jury of experts. The evaluation of the Switzerland awards is based on more than 30 years of observed practice from the global awards programme that has been rolled out in 50+ countries worldwide. This recognition reflects Stallergenes Greer's consistent ability to deliver on its strategic vision while maintaining the operational di
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
